

CASE ON/4-32744A

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

Express Mail Label Number

Date of Deposit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED
CENTRAL FAX CENTER
OCT 01 2008

IN RE APPLICATION OF

Art Unit: 1614

JOSEPH ALEXANDER LASKY

APPLICATION NO: 10/532,297

FILED: AUGUST 24, 2005

FOR: USE OF N-[5-[4-(4-METHYLPIPERAZIOMETHYL)-
BENZOYLAMIDO]-2-METHYLPHENYL]-4-(3-PYRIDYL)-2-
PYRIDINE-AMINE FOR THE TREATMENT OF PULMONARY
HYPERTENSIONCommissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450PETITION FOR EXTENSION OF TIME

Sir:

The Office Action of April 1, 2008 has a shortened statutory time set to expire on July 1, 2008. A three-month extension is hereby requested pursuant to 37 CFR §1.136(a).

Please charge Deposit Account No. 19-0134 in the name of Novartis in the amount of \$1050 for payment of the extension fee. An additional copy of this paper is here enclosed. The Commissioner is hereby authorized to charge any additional fees under 37 CFR §1.17 which may be required, or credit any overpayment, to Account No. 19-0134 in the name of Novartis.

Respectfully submitted,

Novartis Pharmaceuticals Corp.
Patents Pharma
One Health Plaza, Building 104
East Hanover, NJ 07936-1080Date: *October 1, 2008*
George R. Dohmann
Attorney for Applicant
Reg. No. 33,593
Phone No. (862) 778-7824

10/02/2008 VBU11 00000024 190134 10532297

01 FC:1253

1050.00 DA

CASE ON/4-32744A

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

Express Mail Label Number

Date of Deposit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED
CENTRAL FAX CENTER
OCT 01 2008

IN RE APPLICATION OF

Art Unit: 1614

JOSEPH ALEXANDER LASKY

APPLICATION NO: 10/532,297

FILED: AUGUST 24, 2005

FOR: USE OF N-[5-[4-(4-METHYLPIPERAZIOMETHYL)-
BENZOYLAMIDO]-2-METHYLPHENYL]-4-(3-PYRIDYL)-2-
PYRIDINE-AMINE FOR THE TREATMENT OF PULMONARY
HYPERTENSIONCommissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450PETITION FOR EXTENSION OF TIME

Sir:

The Office Action of April 1, 2008 has a shortened statutory time set to expire on July 1, 2008. A three-month extension is hereby requested pursuant to 37 CFR §1.136(a).

Please charge Deposit Account No. 19-0134 in the name of Novartis in the amount of \$1050 for payment of the extension fee. An additional copy of this paper is here enclosed. The Commissioner is hereby authorized to charge any additional fees under 37 CFR §1.17 which may be required, or credit any overpayment, to Account No. 19-0134 in the name of Novartis.

Respectfully submitted,

Novartis Pharmaceuticals Corp.
Patents Pharma
One Health Plaza, Building 104
East Hanover, NJ 07936-1080Date: *October 1, 2008*
George R. Dohmann
Attorney for Applicant
Reg. No. 33,593
Phone No. (862) 778-7824